Long-Acting Corticosteroid (Joint Injection) Pregnancy: Safety of topical corticosteroid use in pregnancy not established; use only if potential benefit justifies potential risk to the foetus, and not extensively in large amounts or for prolonged periods. It is not known whether topical administration produces detectable quantities in breast milk; decide whether to discontinue nursing or the drug.

Betamethasone Dipropionate

Brand names: Celestone Soluspan, Diprospan

Betamethasone dipropionate is a potent long-acting corticosteroid; in the orthopaedic context an injectable betamethasone ester preparation is used for intra-articular and soft-tissue injection to reduce inflammation in joints, bursae and tendon sheaths.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Apply a thin film to cover the affected area (topical betamethasone dipropionate + salicylic acid ointment)

Route: Topical (cutaneous)

Frequency: Once to twice daily (twice daily in most cases)

Max: The maximum weekly dose should not exceed 60 g

SOURCE MISMATCH: the fetched SPC is Diprosalic Ointment, a topical betamethasone dipropionate with salicylic acid product, NOT an intra-articular/joint injection preparation; no joint-injection posology is present in the source. Faithful to source: for some patients adequate maintenance may be achieved with less frequent application; recommended to prescribe for two weeks with review at that time. Occlusion must not be used (keratolytic action of salicylic acid may enhance steroid absorption). Children: dosage should be limited to 5 days; if used in children or on the face, courses should be limited to 5 days. Clinician to source a betamethasone injectable (e.g. betamethasone sodium phosphate/acetate) SPC for intra-articular/soft-tissue joint dosing.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

Rosacea, acne, perioral dermatitis, perianal and genital pruritus
Hypersensitivity to any of the ingredients
Tuberculous and most viral lesions of the skin, particularly herpes simplex, vaccinia, varicella
Napkin eruptions, fungal or bacterial skin infections without suitable concomitant anti-infective therapy

Side effects

Burning, itching, irritation, dryness
Folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation
Local skin atrophy, striae and superficial vascular dilation (with continuous use, particularly on the face)
Perioral dermatitis and allergic contact dermatitis
Topical steroid withdrawal reactions (redness, burning/stinging, itch, skin peeling, oozing pustules); blurred vision

Clinical monograph

How it works

It binds glucocorticoid receptors to suppress the local inflammatory cascade, reducing cytokine production, leucocyte activity and prostaglandin synthesis at the injected site.

Prescribing in practice

Do not inject into a joint or soft tissue if local or systemic infection is suspected, as corticosteroid injection can worsen and mask sepsis; exclude septic arthritis first.
Use aseptic technique and limit the frequency of injections into a single joint, as repeated injections can damage cartilage and surrounding tissue.
Systemic absorption can transiently raise blood glucose and suppress the adrenal axis, and post-injection flare may occur.

Monitoring

Monitor the injected joint for response and signs of infection, and review glycaemic control in patients with diabetes after injection.

Counselling the patient

Some soreness may occur for a day or two after the injection before benefit is felt; rest the joint as advised.
Seek urgent review if the joint becomes hot, increasingly swollen, very painful or you develop a fever.

Evidence & guidelines

Intra-articular corticosteroid injection is an established option for inflammatory joint and soft-tissue conditions, supported by standard musculoskeletal practice guidance.

Reference: NICE CG177 (OA 2022); SPC Diprospan; Cochrane Review (IA steroids for OA knee); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways